Zymeworks Inc. SEDAR Filings

Results 2026-05-14 Returns

Open PDF

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

News release - English.pdf

News 2026-05-13

Open PDF

Zymeworks Announces Participation in Upcoming Investor Conferences

News release - English.pdf

Results 2026-05-07

Open PDF

Interim MD&A - English.pdf

Results 2026-05-07

Open PDF

Interim financial statements/report – English.pdf

Results 2026-05-07

Open PDF

Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results

News release - English.pdf

Results 2026-04-21

Open PDF

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

News release - English.pdf

News 2026-04-17

Open PDF

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

News release - English.pdf

News 2026-03-30

Open PDF

Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRa-Targeting Antibody-Drug Conjugate

News release - English.pdf

News 2026-03-18

Open PDF

Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

News release - English.pdf

News 2026-03-17

Open PDF

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

News release - English.pdf

News 2026-03-02

Other.pdf

Results 2026-03-02 Financials

Open PDF

Annual MD&A - English.pdf

Results 2026-03-02 Financials

Open PDF

Audited annual financial statements – English.pdf

Results 2026-03-02 Financials

Annual report on form 10-K - English.pdf

News 2026-03-02

Other.pdf

News 2026-03-02

Other.pdf

Results 2026-03-02

Open PDF

Zymeworks Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

News release - English.pdf

Transactions 2026-03-02 Financing

Open PDF

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

News release - English.pdf

News 2026-01-27

Open PDF

Zymeworks Announces Participation in Upcoming Investor Conferences

News release - English.pdf

News 2026-01-12

Other.pdf

Results 2026-01-11

Open PDF

Zymeworks Outlines Strategic Priorities and Outlook for 2026

News release - English.pdf

Results 2026-01-06

Open PDF

Zymeworks Announces Positive Efficacy and Safety Results from Phase 3 HERIZON-GEA-01 Trial Evaluating Ziihera® (zanidatamab-hrii) in Combination with Chemotherapy for First-Line HER2+ Locally Advanced or Metastatic GEA

News release - English.pdf

News 2025-12-30

Other.pdf

News 2025-12-02

Open PDF

Zymeworks Announces Participation in Upcoming Conferences

News release - English.pdf

News 2025-11-18

Other.pdf

News 2025-11-18

Open PDF

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

News release - English.pdf

News 2025-11-17

Other.pdf

Results 2025-11-17

Open PDF

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

News release - English.pdf

Results 2025-11-10 Financials